{"id":2079,"date":"2018-03-01T12:41:31","date_gmt":"2018-03-01T12:41:31","guid":{"rendered":"https:\/\/www.medicalmarijuanainc.com\/?p=35188"},"modified":"2018-03-01T12:41:31","modified_gmt":"2018-03-01T12:41:31","slug":"axim-biotechnologies-successfully-applies-proprietary-method-extracting-pure-cannabinoid-molecules","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2018\/03\/01\/axim-biotechnologies-successfully-applies-proprietary-method-extracting-pure-cannabinoid-molecules\/","title":{"rendered":"AXIM\u00ae Biotechnologies Successfully Applies Proprietary Method for Extracting Pure Cannabinoid Molecules"},"content":{"rendered":"

<\/h3>\n

Exclusive process for extracting and microencapsulating cannabinoids allows AXIM\u00ae to create pharmaceutical grade cannabinoid ingredients. <\/span><\/i><\/h3>\n

AXIM\u00ae Biotechnologies leads the industry in cannabinoid research and treatment innovation with 20 separate cannabis-based pharmaceuticals currently in development. <\/span><\/p>\n

Giving AXIM\u00ae a further edge, the company recently announced that it has successfully executed its proprietary current good manufacturing practices (\u201ccGMP\u201d) methods for extraction and microencapsulation of cannabinoid molecules. These high purity, microencapsulated cannabinoids are ideal for development into a variety of pharmaceutical applications. <\/span><\/p>\n

This breakthrough achievement makes AXIM\u00ae Biotechnologies the only company in the world to apply this proprietary procedure to providing pure Active Pharmaceutical Ingredients (\u201cAPIs\u201d) from naturally sourced cannabinoids. <\/span><\/p>\n

Proprietary Method for Cannabinoid Extraction and Purification<\/span><\/h2>\n

AXIM\u00ae Biotechnologies\u2019 unprecedented manufacturing methods begin with carefully cultivated cannabis plants grown in an approved facility. After the plants are harvested, the company extracts the plants oil, including its valuable cannabinoids. In an innovative two-step process that achieves an average cannabinoid purity of more than 99 percent, AXIM\u00ae is able to create the highest quality cannabinoids for use as active pharmaceutical ingredients.<\/span><\/p>\n

\"<\/p>\n

The process, which was developed in the Netherlands under strict regulatory guidelines, follows strict cGMP standards from cultivation through manufacturing to ensure consistently high purity results. <\/span><\/p>\n

AXIM\u00ae Biotechnologies doesn\u2019t use toxic solvents like some traditional cannabinoid extraction processes. Nor are its resulting cannabinoids synthesized like the API dronabinol. Instead, AXIM\u00ae creates its cannabinoid APIs from all-natural cannabis plants. <\/span><\/p>\n

Pharmaceutical Grade Encapsulated Cannabinoids<\/span><\/h2>\n

After the extraction and purification of the cannabinoids, AXIM\u00ae applies its newly developed microencapsulation method is applied to the cannabinoids. <\/span><\/p>\n

Microencapsulation surrounds an active material core with an outer shell or membrane. This microencapsulation protects the cannabinoid core from deterioration from oxidation, etc., while preserving effectiveness. Microencapsulation can also be used to <\/span>control the release of active ingredients<\/span><\/a> and can potentially increase bioavailability of APIs. <\/span><\/p>\n

\u201cWe\u2019re thrilled to be able to announce this new method to the industry,\u201d said George E. Anastassov, MD, DDS, MBA, and Chief Executive Officer of AXIM Biotech. \u201cOur innovative extraction process achieves reliable and effective results while providing a high purity level. By microencapsulating these molecules, we are able to protect them and preserve the APIs while increasing their bioavailability and the potential therapeutic benefits for a variety of pharmaceutical applications.\u201d<\/span><\/p>\n

AXIM\u00ae Biotechnologies then formulates its microencapsulated cannabinoids into a number of pharmaceutical products. Due to the microencapsulated cannabinoids\u2019 versatility in use, it is manufactured into transdermal delivery systems, suppositories, capsules, ocular applications, and its patented cannabinoid chewing gum. <\/span><\/p>\n

AXIM\u00ae Looks to Create Novel Cannabinoid-Based Treatments<\/span><\/h2>\n

Using these delivery systems, AXIM\u00ae Biotechnologies is developing a number of cannabinoid-based pharmaceutical treatments, many for hard to treat medical indications. AXIM\u00ae currently owns two patents and is awaiting confirmation of an additional 12 patent applications.<\/span><\/p>\n

\"medical<\/p>\n

To date, AXIM\u00ae has formulated over 20 diversified products, targeting conditions that include<\/span><\/p>\n